Brexit and the pharmaceutical sector

Together with the Ministry of Social Affairs and Health, other authorities and operators, Fimea has prepared for Brexit, i.e. withdrawal of the United Kingdom from the European Union.

Fimea and other pharmaceutical operators have mapped possible disturbances in the pharmaceutical services and the related risks. Cooperative measures have been initiated to prevent potential disruptions.

The situation picture is updated continually and efforts are continued in close cooperation to ensure uninterrupted patient treatment.

Read more:

Information about Brexit (Prime Minister's Office)

Questions & answers: EU actions to prevent medicine shortges due to Brexit (EMA 26/03/2019)

Common guidelines from the Commission to prevent problems in the supply of medicines

Brexit related batch control testing exemption request submissions to Fimea

Preparations for Brexit well underway in the pharmaceutical industry

Marketing Authorisation Holders should prepare for Brexit

Frequently asked questions

Preparations for Brexit in social security provision and pharmaceutical service (

Marketing Authorisations